These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37139547)

  • 1. In-silico identification of novel DDI2 inhibitor in glioblastoma
    Roy PK; Majumder R; Mandal M
    J Biomol Struct Dyn; 2024 Mar; 42(5):2270-2281. PubMed ID: 37139547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction.
    Koizumi S; Irie T; Hirayama S; Sakurai Y; Yashiroda H; Naguro I; Ichijo H; Hamazaki J; Murata S
    Elife; 2016 Aug; 5():. PubMed ID: 27528193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disabling the Protease DDI2 Attenuates the Transcriptional Activity of NRF1 and Potentiates Proteasome Inhibitor Cytotoxicity.
    Northrop A; Vangala JR; Feygin A; Radhakrishnan SK
    Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31947743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian Ddi2 is a shuttling factor containing a retroviral protease domain that influences binding of ubiquitylated proteins and proteasomal degradation.
    Collins GA; Sha Z; Kuo CL; Erbil B; Goldberg AL
    J Biol Chem; 2022 May; 298(5):101875. PubMed ID: 35358511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
    Arodola OA; Soliman ME
    Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
    Gu Y; Wang X; Wang Y; Wang Y; Li J; Yu FX
    Cell Signal; 2020 Nov; 75():109775. PubMed ID: 32916277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.
    Op M; Ribeiro ST; Chavarria C; De Gassart A; Zaffalon L; Martinon F
    Cell Death Dis; 2022 May; 13(5):475. PubMed ID: 35589686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing antiviral drugs against HTLV-1 protease by molecular docking and molecular dynamics simulation.
    Jahantigh H; Ahmadi N; Lovreglio P; Stufano A; Enayatkhani M; Shahbazi B; Ahmadi K
    J Biomol Struct Dyn; 2023 Jul; 41(11):5057-5066. PubMed ID: 35612907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival.
    Chen T; Ho M; Briere J; Moscvin M; Czarnecki PG; Anderson KC; Blackwell TK; Bianchi G
    Blood Adv; 2022 Jan; 6(2):429-440. PubMed ID: 34649278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the dual effects of antiviral drugs on SARS-CoV-2 receptors and the ACE2 receptor using structure-based virtual screening and molecular dynamics simulation.
    Jahantigh HR; Ahmadi N; Shahbazi B; Lovreglio P; Habibi M; Stufano A; Gouklani H; Ahmadi K
    J Biomol Struct Dyn; 2023; 41(13):6051-6073. PubMed ID: 35876061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing of FDA approved drugs against
    Joshi T; Sharma P; Joshi T; Mathpal S; Pande V; Chandra S
    J Biomol Struct Dyn; 2022 May; 40(8):3731-3744. PubMed ID: 33251976
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    El-Hddad S; Sobhy M; Ayoub A; El-Adl K
    J Biomol Struct Dyn; 2023 Nov; 41(19):9267-9281. PubMed ID: 36399002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug repurposing against the RNA-dependent RNA polymerase domain of dengue serotype 3 by virtual screening and molecular dynamics simulations.
    Gangopadhyay A; Saha A
    J Biomol Struct Dyn; 2023 Jul; 41(11):5152-5165. PubMed ID: 35642087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1.
    Dirac-Svejstrup AB; Walker J; Faull P; Encheva V; Akimov V; Puglia M; Perkins D; Kümper S; Hunjan SS; Blagoev B; Snijders AP; Powell DJ; Svejstrup JQ
    Mol Cell; 2020 Jul; 79(2):332-341.e7. PubMed ID: 32521225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating the NFE2L1-ubiquitin-proteasome system by DDI2 protects from ferroptosis.
    Ofoghi A; Kotschi S; Lemmer IL; Haas DT; Willemsen N; Bayer B; Jung AS; Möller S; Haberecht-Müller S; Krüger E; Krahmer N; Bartelt A
    Cell Death Differ; 2024 Oct; ():. PubMed ID: 39384955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Tian X; Ye J; Alonso-Basanta M; Hahn SM; Koumenis C; Dorsey JF
    J Biol Chem; 2011 Aug; 286(33):29408-29416. PubMed ID: 21697087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic drug repurposing approach to identify promising inhibitors from FDA-approved drugs against Nsp4 protein of SARS-CoV-2.
    Chakraborty J; Maity A; Sarkar H
    J Biomol Struct Dyn; 2023 Feb; 41(2):550-559. PubMed ID: 34844509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma.
    Peñaranda Fajardo NM; Meijer C; Kruyt FA
    Biochem Pharmacol; 2016 Oct; 118():1-8. PubMed ID: 27106078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.